Brean Capital Reiterates Bearish Position On Vivus Shares, But Keeps $4 PT
Brean Capital analyst Jonathan Aschoff reiterated a Sell rating on Vivus (NASDAQ:VVUS), while keeping his price target at $4, which represents a potential upside of 18% from where the stock is currently trading. Are you confused? so are we.
Aschoff noted, “We believe that Belviq will continue, and Contrave will start, to pressure Qsymia sales, especially given the larger salesforces of both competitors.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 11.2% and a 57.6% success rate. Aschoff has a -9.1% average return when recommending VVUS, and is ranked #250 out of 3364 analysts.